JP2015535291A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535291A5 JP2015535291A5 JP2015540844A JP2015540844A JP2015535291A5 JP 2015535291 A5 JP2015535291 A5 JP 2015535291A5 JP 2015540844 A JP2015540844 A JP 2015540844A JP 2015540844 A JP2015540844 A JP 2015540844A JP 2015535291 A5 JP2015535291 A5 JP 2015535291A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- amount
- therapeutically effective
- effective amount
- pomalidomide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010062237 Renal impairment Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 1
- 229960000688 pomalidomide Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722722P | 2012-11-05 | 2012-11-05 | |
| US61/722,722 | 2012-11-05 | ||
| US201361764466P | 2013-02-13 | 2013-02-13 | |
| US61/764,466 | 2013-02-13 | ||
| PCT/US2013/068237 WO2014071280A1 (en) | 2012-11-05 | 2013-11-04 | Treatment of cancer with pomalidomide in a renally impaired subject |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015535291A JP2015535291A (ja) | 2015-12-10 |
| JP2015535291A5 true JP2015535291A5 (enExample) | 2016-12-28 |
Family
ID=50628132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540844A Pending JP2015535291A (ja) | 2012-11-05 | 2013-11-04 | 腎臓に障害のある対象におけるポマリドミドを用いる癌の治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20150297579A1 (enExample) |
| EP (1) | EP2914112A4 (enExample) |
| JP (1) | JP2015535291A (enExample) |
| CN (1) | CN104902754A (enExample) |
| AU (1) | AU2013337352A1 (enExample) |
| BR (1) | BR112015010039A2 (enExample) |
| CA (1) | CA2889987A1 (enExample) |
| EA (1) | EA201590883A1 (enExample) |
| HK (1) | HK1214552A1 (enExample) |
| IL (1) | IL238563A0 (enExample) |
| MX (1) | MX2015005548A (enExample) |
| NI (1) | NI201500063A (enExample) |
| PH (1) | PH12015501002A1 (enExample) |
| SG (1) | SG11201503456TA (enExample) |
| WO (1) | WO2014071280A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507759WA (en) * | 2013-04-02 | 2015-10-29 | Celgene Corp | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
| WO2019051125A1 (en) | 2017-09-06 | 2019-03-14 | Translational Drug Development, Llc | AMINOBENZIMIDAZOLE DERIVATIVES, TREATMENTS AND METHODS FOR INHIBITING HISTONE DEACETYLASE |
| EP3297674B1 (en) * | 2015-05-22 | 2023-01-04 | Translational Drug Development Llc | Benzamide and active compound compositions and methods of use |
| CN105456232A (zh) * | 2015-09-08 | 2016-04-06 | 刘剑 | 一种泊马度胺速溶膜剂及其制备方法 |
| AU2016394945A1 (en) * | 2016-03-02 | 2018-10-11 | Translational Drug Development Llc | Aminobenzimidazole derivatives |
| WO2018013689A1 (en) * | 2016-07-13 | 2018-01-18 | Celgene Corporation | Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof |
| CN108721304B (zh) * | 2017-04-17 | 2020-10-16 | 北京大学 | 用于治疗肿瘤的药物组合物及其用途 |
| AR119715A1 (es) | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| GB202012160D0 (en) * | 2020-08-05 | 2020-09-16 | Vicore Pharma Ab | New compositions |
| EP4479082A2 (en) * | 2022-02-15 | 2024-12-25 | The Broad Institute, Inc. | Cell-type specific targeting contractile injection system |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| JP5339588B2 (ja) * | 2008-11-10 | 2013-11-13 | 国立大学法人 新潟大学 | サリドマイドまたはその誘導体を有効成分とする統合失調症の治療薬 |
| JP5553275B2 (ja) * | 2010-03-31 | 2014-07-16 | 国立大学法人金沢大学 | 金属錯体およびこれを有効成分として含有する抗がん剤 |
| JP2014517915A (ja) * | 2011-04-18 | 2014-07-24 | セルジーン コーポレイション | 多発性骨髄腫治療のためのバイオマーカー |
| EP3096142A3 (en) * | 2011-04-29 | 2017-03-08 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
-
2013
- 2013-11-04 US US14/440,333 patent/US20150297579A1/en not_active Abandoned
- 2013-11-04 AU AU2013337352A patent/AU2013337352A1/en not_active Abandoned
- 2013-11-04 MX MX2015005548A patent/MX2015005548A/es unknown
- 2013-11-04 EP EP13850977.3A patent/EP2914112A4/en not_active Withdrawn
- 2013-11-04 CA CA2889987A patent/CA2889987A1/en not_active Abandoned
- 2013-11-04 EA EA201590883A patent/EA201590883A1/ru unknown
- 2013-11-04 BR BR112015010039A patent/BR112015010039A2/pt not_active IP Right Cessation
- 2013-11-04 JP JP2015540844A patent/JP2015535291A/ja active Pending
- 2013-11-04 CN CN201380069405.4A patent/CN104902754A/zh active Pending
- 2013-11-04 HK HK16102558.2A patent/HK1214552A1/zh unknown
- 2013-11-04 SG SG11201503456TA patent/SG11201503456TA/en unknown
- 2013-11-04 WO PCT/US2013/068237 patent/WO2014071280A1/en not_active Ceased
-
2015
- 2015-04-30 IL IL238563A patent/IL238563A0/en unknown
- 2015-05-04 NI NI201500063A patent/NI201500063A/es unknown
- 2015-05-05 PH PH12015501002A patent/PH12015501002A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015535291A5 (enExample) | ||
| CL2015003022A1 (es) | Uso de empagliflozina en la preparacion de un medicamento util en el tratamiento de la enfermedad renal cronica | |
| DK3730136T3 (da) | Anvendelse af ferricitrat til behandlingen af patienter med kronisk nyresygdom | |
| EA201500997A1 (ru) | Терапевтические применения эмпаглифлозина | |
| CL2013001602A1 (es) | Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple. | |
| JP2012143233A5 (enExample) | ||
| EP2968306A4 (en) | ADMINISTRATION OF NICOTINAMIDE MONONUCLEOTIDE IN THE TREATMENT OF DISEASES | |
| HK1214552A1 (zh) | 在腎損傷的受試者中用泊馬度胺治療癌症 | |
| MX2015013166A (es) | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. | |
| HUE054783T2 (hu) | Pridopidin Huntington-kór kezelésében | |
| MX366317B (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
| EP3071280A4 (en) | TREATMENT CATHETER WITH THERAPEUTIC ENERGY SUPPLY | |
| JP2015522522A5 (enExample) | ||
| IL245317A0 (en) | Ferric citrate for reducing cardiac failure in chronic kidney disease patients | |
| HRP20190122T1 (hr) | Protutijelo protiv adrenomedulina (adm) ili fragment protutijela protiv adm ili okosnica ne-ig protiv adm, namijenjeni reguliranju ravnoteže tekućina kod pacijenta s kroničnom ili akutnom bolešću | |
| MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
| JP2014507659A5 (enExample) | ||
| JP2015502958A5 (enExample) | ||
| JP2013231052A5 (enExample) | ||
| PE20160221A1 (es) | Formas de dosificacion farmaceuticas estabilizadas que comprenden atrasentan | |
| EA201591450A1 (ru) | Фармацевтический состав, содержащий гликозаминогликан | |
| EP2959905A4 (en) | ORAL ADMINISTRATIVE ADSORBENT, THERAPEUTIC AGENT AGAINST CHILDING DISEASE AND THERAPEUTIC AGENT AGAINST LIVER DISEASES | |
| EP2959906A4 (en) | ADSORBENT FOR ORAL ADMINISTRATION, MEDICAMENT FOR RENAL DISEASE, AND MEDICAMENT FOR LIVER DISEASE | |
| EP2959908A4 (en) | ORAL ADMINISTRATIVE ADSORBENT, THERAPEUTIC AGENT AGAINST CHILDING DISEASE AND THERAPEUTIC AGENT AGAINST LIVER DISEASES | |
| BRPI1009322A2 (pt) | dose de ave5026 para o tratamento de tromboembolia venosa em pacientes com deficiência renal grave |